Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer

  • Camillo Porta | c.porta@smatteo.pv.it Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital Foundation, Pavia, Italy.

Abstract

In the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin—the only treatment then available—first, the development of irinotecan and oxaliplatin, and then the use of the two biologicals, bevacizumab and cetuximab, have dramatically improved the life expectancy of our colorectal cancer patients...

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-14
Info
Issue
Section
Editorials
Statistics
  • Abstract views: 881

  • FULL TEXT: 141
How to Cite
Porta, C. (2011). Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer. Oncology Reviews, 3(1), 1-2. https://doi.org/10.4081/oncol.2009.1